ArticleFrontiers in oncology2024
[
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Article
- Molecular Brain Tumor Imaging Beyond [AJR. American journal of roentgenology · 2026Review
- Comparative Insights intoMolecular imaging and radionuclide therapy · 2026Article
- Noninvasive tracking of myocardial fibrosis in pressure-overload heart failure with [EJNMMI research · 2026Article
- [⁶⁸Ga]Ga-FAPI-46 PET/CT imaging in neuromelioidosis: a case series demonstrating potential utility in diagnosis and response assessment.EJNMMI reports · 2026Article
- The superiority of [European journal of nuclear medicine and molecular imaging · 2026Article
- Comparison between [EJNMMI research · 2026Article
- Intra-Arterial Radioligand Therapy in Brain Cancer: Bridging Nuclear Medicine and Interventional Neuroradiology.Diagnostics (Basel, Switzerland) · 2026Review
- Targeting FAP/CAFs to rewire immune-excluded and resistant tumor niches.Frontiers in pharmacology · 2026Review
- Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.European journal of nuclear medicine and molecular imaging · 2025Article
- FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?Annals of nuclear medicine · 2025Review
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Context-specific targeting of focal adhesion kinase in brain tumors: lessons from glioblastoma and neurofibromatosis type 2-mutant meningioma.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the feasibility of [ Methods: 25 patients with MRI-suspected brain tumors were included in the study. They underwent whole body [ Result: [ Conclusions: [ Advances in knowledge: Clinical utility of [
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.